Astellas reported that its subsidiary, Xyphos Biosciences, & Poseida have signed a research collaboration & license agreement for developing new convertible CAR products using each company’s expertise
Under the collaboration, Poseida’s allogeneic CAR-T platform & Xyphos’ ACCEL technology will be merged to create a single CAR-T construct for 2 convertible CAR product candidates addressing solid tumors
Poseida will obtain $50M upfront, a total of $550M incl. development & sales milestones plus contingency payments along with low double-digit tiered royalties as a percentage of net sales. Furthermore, Xyphos will cover Poseida’s research costs & handle future product development & commercialization
Ref: Astellas | Image: Astellas
Related News:- Astellas and Pfizer Report the NMPA’s Acceptance of sBLA for Enfortumab Vedotin Plus Keytruda for Treating 1L Bladder Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
